Pharmaceutical

Adcendo and Multitude ink ADC deal potentially worth $1bn

Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.

Aug 21, 2024 - 04:00
Adcendo and Multitude ink ADC deal potentially worth $1bn
Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.
Read the original article

Tags:

Previous Article

Researchers teaching artificial intelligence about frustration in protein folding

Next Article

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Lenmeldy becomes world’s most expensive drug

Lenmeldy becomes world’s most expensive drug

Apr 3, 2024

Opinion: Without a plan to fight superbugs, the Cancer Moonshot will never achieve liftoff

Opinion: Without a plan to fight superbugs, the Cancer ...

Aug 3, 2023

ADCs dominate with billion-dollar licensing agreements in 2022

ADCs dominate with billion-dollar licensing agreements ...

Oct 5, 2023